Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald M Goldenberg

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Diabetes, Obesity & Metabolism|October 22, 2016
Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trialsLawrence Blonde, Pavan Chava, Terry Dex, et al.
Diabetes, Obesity & Metabolism|May 1, 2018
A practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetesRonald M Goldenberg, Peter Assimakopoulos, Jeremy D Gilbert, et al.
Diabetes, Obesity & Metabolism|June 12, 2019
Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA ProtocolRonald M Goldenberg, Jeremy D Gilbert, Irene M Hramiak, et al.
Canadian Journal of Diabetes|November 15, 2020
Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 DiabetesRonald M Goldenberg, Vineeta Ahooja, Kristin K Clemens, et al.
Stroke|March 9, 2022
Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for NeurologistsRonald M Goldenberg, Alice Y Y Cheng, Tess Fitzpatrick, et al.
Obesity Reviews : an Official Journal of the International Association for the Study of Obesity|November 16, 2023
Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonistsRonald M Goldenberg, Jeremy D Gilbert, Priya Manjoo, et al.
Current Opinion in Cardiology|April 30, 2021
The role of icosapent ethyl in cardiovascular risk reductionRonald M Goldenberg, Alice Y Y Cheng, Jeremy D Gilbert, et al.
Current Opinion in Cardiology|December 6, 2019
Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: clinical pearls for in-hospital initiation, in-hospital management, and postdischargeC David Mazer, Amel Arnaout, Kim A Connelly, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 30, 2025
Perioperative and Periprocedural Management of Once-Weekly Insulin Treated PatientsRobyn L Houlden, Jeremy D Gilbert, Tayyab S Khan, et al.
Clinical Therapeutics|December 23, 2016
SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and DiagnosisRonald M Goldenberg, Lori D Berard, Alice Y Y Cheng, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Diabetes, Obesity & Metabolism|October 22, 2016
Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trialsLawrence Blonde, Pavan Chava, Terry Dex, et al.
Diabetes, Obesity & Metabolism|May 1, 2018
A practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetesRonald M Goldenberg, Peter Assimakopoulos, Jeremy D Gilbert, et al.
Diabetes, Obesity & Metabolism|June 12, 2019
Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA ProtocolRonald M Goldenberg, Jeremy D Gilbert, Irene M Hramiak, et al.
Canadian Journal of Diabetes|November 15, 2020
Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 DiabetesRonald M Goldenberg, Vineeta Ahooja, Kristin K Clemens, et al.
Stroke|March 9, 2022
Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for NeurologistsRonald M Goldenberg, Alice Y Y Cheng, Tess Fitzpatrick, et al.
Obesity Reviews : an Official Journal of the International Association for the Study of Obesity|November 16, 2023
Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonistsRonald M Goldenberg, Jeremy D Gilbert, Priya Manjoo, et al.
Current Opinion in Cardiology|April 30, 2021
The role of icosapent ethyl in cardiovascular risk reductionRonald M Goldenberg, Alice Y Y Cheng, Jeremy D Gilbert, et al.
Current Opinion in Cardiology|December 6, 2019
Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: clinical pearls for in-hospital initiation, in-hospital management, and postdischargeC David Mazer, Amel Arnaout, Kim A Connelly, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 30, 2025
Perioperative and Periprocedural Management of Once-Weekly Insulin Treated PatientsRobyn L Houlden, Jeremy D Gilbert, Tayyab S Khan, et al.
Clinical Therapeutics|December 23, 2016
SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and DiagnosisRonald M Goldenberg, Lori D Berard, Alice Y Y Cheng, et al.
Pageof 5